Evidence map›Paper›PMID 41737232›Full record

ArticleFrontiers in immunology2026

Multifunctional theranostic magnetic PLGA nanoparticles encapsulating cyclosporine A: addressing challenges in pancreas transplantation for type 1 diabetes.

Cátia Vieira Rocha, Andreia Patrícia Magalhães, Lara Diego-González, Victor Gonçalves, Martin Kotrulev, Iria Gomez-Touriño, Manuel Bañobre-López, Juan Gallo

Abstract read
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Cátia Vieira RochaInternational Iberian Nanotechnology Laboratory, Braga, Portugal.
Andreia Patrícia MagalhãesInternational Iberian Nanotechnology Laboratory, Braga, Portugal.
Lara Diego-GonzálezInternational Iberian Nanotechnology Laboratory, Braga, Portugal.
Victor GonçalvesInternational Iberian Nanotechnology Laboratory, Braga, Portugal.
Martin KotrulevCentre for Research in Molecular Medicine and Chronic Diseases (CiMUS), University of Santiago de Compostela, Santiago de Compostela, Spain.
Iria Gomez-TouriñoCentre for Research in Molecular Medicine and Chronic Diseases (CiMUS), University of Santiago de Compostela, Santiago de Compostela, Spain.
Manuel Bañobre-LópezInternational Iberian Nanotechnology Laboratory, Braga, Portugal.
Juan GalloInternational Iberian Nanotechnology Laboratory, Braga, Portugal.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Type 1 Diabetes (T1D) is a high-incidence chronic autoimmune disease, with patients requiring lifelong insulin therapy. In the most severe cases, pancreas transplantation (PTA) arises as the first choice of treatment for these patients in the hope of achieving insulin independence. However, the long-term success of PTA is hindered by ischemia-reperfusion injury (IRI) and immune rejection, both of which limit graft survival. To address these challenges, we have developed multifunctional theranostic nanoparticles (t-PLGA NPs) co-encapsulating Fe

Indexed as

CyclosporineDiabetes Mellitus, Type 1Immunosuppressive AgentsMagnetite NanoparticlesPancreas TransplantationPolylactic Acid-Polyglycolic Acid CopolymerTheranostic NanomedicineAnimalsGraft RejectionHumansMagnetic Resonance ImagingManganese CompoundsOxidesCyclosporineImmunosuppressive AgentsMagnetite NanoparticlesManganese Compoundsmanganese oxideOxidesPolylactic Acid-Polyglycolic Acid Copolymerhypoxiamagnetic nanocompositesMRIpancreas transplantationtheranosticstype 1 diabetes

Identifiers

PMID41737232
PMCPMC12926096

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.